Xenetic Biosciences Collaborates with PeriNess for Lymphoma Study

Xenetic Biosciences, Inc. has announced a new clinical study with its partner, PeriNess, focusing on DNase I therapy combined with anti-CD19 CAR T cells for large B cell lymphoma patients. Conducted at Tel Aviv Sourasky Medical Center, Dr. Ron Ram will lead the study aimed at exploring safety and efficacy.

Main objectives include examining DNase I's impact on CAR T-cell function by targeting Neutrophil Extracellular Traps (NETs). Xenetic reports that preclinical models show this approach may reduce tumor burden and prolong survival. This study addresses the challenge of lymphoma relapse, a significant hurdle in CAR T therapies.

Xenetic's CEO, James Parslow, expressed optimism about gathering more data to advance DNase I’s potential. This collaboration aligns with Xenetic's broader strategy to tackle difficult cancers through innovative immuno-oncology treatments.